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AbstrACt
Objective This population-based cohort study assesses 
the impact of switching from a 7-valent pneumococcal 
conjugate vaccine (PCV) to a 10-valent PCV on outpatient 
antibiotic use in Dutch infants, and whether geographical 
vaccination coverage modifies this association.
setting and participants We extracted 2006–2013 
anonymised antibiotic purchase data of 255 154 Dutch 
infants aged below 2 years from Achmea Health, a health 
insurance fund covering 28% of the national population.
Design and main outcome measure Changes in 
monthly antibiotic use from 2006–2011 (PCV7) to 
2011–2013 (PCV10) were estimated using time-series 
analysis accounting for seasonality and autocorrelation. 
Interaction terms for vaccination coverage (categorised 
into seven groups) and period were added to the model to 
test whether this association was vaccination coverage-
dependent.
results 275 337 antibiotic courses were used by 119 078 
infants (461 352 person-years). PCV10 introduction was 
associated with a modest 1.6% overall reduction in 
antibiotic use (purchase rate ratio: 0.98, 95% CI: 0.98 
to 0.99). Our model showed a significant difference in 
time trend in antibiotic use after PCV10 introduction 
(p=0.0084) with an increase in prescriptions in the PCV7 
period (slope: 0.0023/month, 95% CI: −0.0001 to 0.0047) 
versus a decline in the PCV10 period (slope: −0.0089/
month, 95% CI: −0.0150 to −0.0029). There was no 
evidence that PCV vaccination coverage affected this 
association, but since the largest rate ratios were observed 
in municipalities with the lowest vaccine coverage and 
had very wide accompanying CIs, our study might have 
insufficient power to detect such an association.
Conclusions Switching from PCV7 to PCV10 was 
associated with a modest decline in outpatient antibiotic 
use in Dutch infants.
IntrODuCtIOn 
Antibiotics represent the most commonly 
prescribed therapeutic agents in childhood 
worldwide. Up to 90% of all childhood antibi-
otics are prescribed in primary care,1 2 and 80% 
of those are for respiratory tract infections.3 
Its routine use for common primary care 
infections favours the emergence of antibi-
otic resistance and with increasing resistance 
effective treatment of bacterial infections is 
threatened.4 Previous research has shown 
that introduction of pneumococcal conjugate 
vaccines (PCV) in childhood reduced pneu-
mococcal disease incidence and subsequent 
antibiotic prescription rates, thereby limiting 
the spread of antibiotic resistance.5–9 These 
reductions, however, have been reported 
in countries where either antibiotic use is 
high,10 where childhood respiratory tract 
infections were already on the decline,11 12 
or where new guidance on judicious use of 
antibiotics was introduced during the obser-
vational period.13 
We, therefore, set out to study the impact 
of switching from a 7-valent PCV to a 
10-valent PCV on outpatient antibiotic use 
in infants in the Netherlands where reliable 
longitudinal data on outpatient antibiotic 
purchases are held by the Dutch insurance 
strengths and limitations of this study
 ► Anonymised nationwide outpatient antibiotic pur-
chase data were extracted from a large insurance 
fund that provides obligatory health insurance.
 ► Quasi-experimental approach using interrupted 
time-series analysis to study longitudinal effects of 
interventions using observational data.
 ► To reduce potential confounding, regression analy-
ses were used to assess whether vaccination cov-
erage modified the association between vaccination 
and antibiotic purchases.
 ► There was a potential for unmeasured confounding 
due to the observational nature of the study.
 ► This study did not include data from before 2006 
and with the most prominent decline seen in 2013, 
future work should include longer follow-up data.
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funds that provide obligatory health insurance,14 and 
where judicious antibiotic use has been promoted since 
the 1980s resulting in low antibiotic prescribing and 
resistance rates.15–17 In addition, vaccination coverage is 
closely monitored across all Dutch municipalities by the 
National Institute for Public Health and the Environment 
(RIVM),18 allowing us to study whether geographical PCV 
coverage modifies this association.
PAtIents AnD methODs
In the Dutch healthcare system, all citizens have a basic 
obligatory healthcare insurance which covers costs of 
medication.14 In this observational cohort study, we used 
anonymised outpatient antibiotic purchase data from 
Achmea Health, one of the largest health insurance 
funds covering 4.8 million individuals (28% of the Dutch 
population). The population insured by Achmea Health 
represents the urbanised area of the Netherlands with 
regard to age, sex and socioeconomic status.14 All children 
born between January 2006 and February 2013 and regis-
tered with Achmea Health within the first 6 months of life 
were included and follow-up started from birth onwards. 
With an annual birth cohort ranging from 185.057 (in 
2006) to 171.341 (in 2013), our study population covered 
19% of the total Dutch birth cohort. They were followed 
up until sensor date, that is until 2 years of age, or until 
they left the insurance fund or until the end of our study 
period (31 December 2013).
The Dutch National Immunisation Program (NIP) intro-
duced PCV7 for all infants born as from 1 April 2006. The 
NIP switched from PCV7 to PCV10 for infants born as from 
1 March 2011. PCV7 and PCV10 initially were given at ages 
2, 3, 4 and 11 months. A three-dose schedule at ages 2, 4 
and 11 months was implemented for children born as from 
1 November 2013. Although PCV vaccination coverage on 
average has been stable and high at 94.4%–95.1% (median: 
94.8%) since its introduction in 2006, there is considerable 
geographical variation across the 393 Dutch municipali-
ties, and PCV vaccination coverage data were available for 
all municipalities.18 We obtained PCV vaccination coverage 
data for all 393 municipalities as reported by the RIVM in 
201218 19 and categorised municipalities into seven groups 
(<70.0%, 2 municipalities with 746 children; 70.0%–74.9%, 
3 municipalities with 2043 children; 75.0%–79.9%, 5 munic-
ipalities with 1437 children; 80.0%–84.9%, 9 municipali-
ties with 2131 children; 85.0%–89.9%, 27 municipalities 
with 9357 children; 90.0%–94.9%, 112 municipalities with 
96 274 children; 95.0%–100.0%, 231 municipalities with 
143 166 children). Categorisation was done in a stepwise 
process: we (1) obtained PCV vaccination coverage data by 
municipality, (2) linked municipality by their unique postal 
codes, (3) linked the postal code available for every child 
to a specific municipality and its vaccination coverage (4) 
allocated a child to one of the seven categories.
We used Anatomical Therapeutic Chemical codes 
to extract data on the most commonly prescribed anti-
biotics in respiratory tract infections17 20 in children in 
The Netherlands: amoxicillin (J01CA04), amoxicillin/
clavulanic acid (J01CR02), phenoxymethylpenicillin 
(J01CE02), pheneticillin (J01CE05), trimethoprim/
sulfamethoxazole (J01EE01), clarithromycin (J01FA09) 
and azithromycin (J01FA10). Infant antibiotic purchase 
data were available for 389 of the 393 (99%) Dutch 
municipalities.
Patient and public involvement
There was no patient or public involvement in the study.
statistical analysis
The total number of children at risk per month (person-
time) and region was calculated using date of birth, 
postal code, registration date and sensor date for each 
child in the Achmea Health Database. Using the anti-
biotic purchase date, the total number of antibiotic 
purchases per month and region was calculated. Crude 
monthly antibiotic purchase rates per 1000 child-months 
and its 95% CI were calculated by dividing the number 
of observed antibiotic purchases by the total number of 
observed child-months for the period 2006–2013 using 
Poisson exact test. The purchase rate ratio (RR) was 
calculated per municipality by dividing the antibiotic 
prescription rate after PCV10 implementation over the 
rate before PCV10 implementation. The percentage of 
change as a measure of vaccine impact was calculated by 
1-RR⨉100%.21
Next, monthly antibiotic purchases were estimated by 
negative binomial regression analysis, using the natural 
logarithm of the number of antibiotic purchases per month 
as the outcome and the natural logarithm of the number 
of children ‘at risk’ as an offset variable. The model can be 
written as: ln(Yt)=β0+β1×time+β2×factor (month)+β3×peri-
od+β4×[period ×time]+β5×[lag]+β6×[lag2]+ln[offset]. 
Here, Yt is the mean number of prescriptions per child 
in month t; time is a continuous variable indicating 
time in months at time t from the start of the observa-
tion period; period is an indicator from time t occurring 
before (period=0; January 2006 to February 2011) or 
after (period=1; March 2011 to December 2013) the start 
of PCV10 vaccination that was implemented at month 
63 in the series. An interaction between ‘time⨉period’ 
was used to assess the level and change after the intro-
duction of PCV10 on antibiotic purchases; a combina-
tion of calendar month and 1-month and 2-month lag 
terms were used to adjust for seasonality and autocorrela-
tion.22 23 In this model, the intercept (β0) estimates the 
baseline level of the outcome, mean number of prescrip-
tions per patient per month, at time 0; β1 estimates the 
change in the mean number of prescriptions per patient 
that occurs with each month before the intervention (ie, 
the baseline trend); β3 estimates the level change in the 
mean monthly number of prescriptions; and β4 estimates 
the change in the trend in the mean monthly number 
of prescriptions per patient after PCV10 introduction 
(period=1), compared with the monthly trend before. 
The sum of β1 and β4 is the post-PCV10 slope. This model 
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is often referred to as interrupted time series analysis.22 A 
goodness of fit test was used to compare the model to the 
observed data. To test whether there was a difference in 
time trends before and after the introduction of PCV10, 
we compared this model with one without the period and 
period×time effects (assuming the same intercept and 
slope over time for the two periods) using a likelihood 
ratio test. Inspection of residuals was performed to detect 
normality, linearity, homoscedasticity and autocorrela-
tion.22 23
In a sensitivity analysis, we excluded the first 2 years 
of observations (both follow-up time and antibiotic 
prescriptions) since none of the subjects reached the age 
of 2 years during this period. In a further sensitivity anal-
ysis, coverage was added to the main model, along with 
its interactions with period and time to assess whether 
the level and change of antibiotic prescriptions differ by 
period, time and vaccination coverage. All statistical anal-
yses were performed using SPSS V.24.0 and the R statis-
tical software system V.0.98.1103 (RStudio).
results
Over the years 2006–2013, 255 154 infants (51% boys) 
were followed for 461 352 child-years (mean duration of 
follow-up per child: 21.7 months, SD: 4.9 months). A total 
of 275 337 antibiotics were used in 119 078 infants (47% 
of infants, of which 55% were boys). With 201 797 courses 
(73% of total purchases), amoxicillin was most commonly 
used. Mean outpatient antibiotic purchase prescription 
rates during the PCV7 and PCV10 periods were 601 (95% 
CI: 598 to 604) and 591 (95% CI: 588 to 595) per 1000 
child-years, respectively (table 1). These data indicate 
that PCV10 introduction was associated with a modest 
reduction in outpatient antibiotic use of 1.6% (RR=0.984, 
95% CI: 0.977 to 0.992).
The goodness of fit test indicated that our time-series 
model fitted the observed data (p=0.06, figure 1). Model-
ling allowed for estimation of linear trends over the two 
periods, with antibiotic rates slightly increasing over the 
PCV7 period (slope: 0.0023/month, 95% CI: −0.0001 
to 0.0047) versus a decline in the PCV10 period (slope: 
−0.0089/month, 95% CI: −0.0150 to −0.0029). The like-
lihood ratio test showed a significant difference in time 
trend after PCV10 introduction (p=0.0084) (figure 1).
The sensitivity analysis in which the first 2 years of 
observations (2006 and 2007) were excluded also showed 
a significant difference in time trend after PCV10 intro-
duction, but with a more or less stable trend in the PCV7 
period (slope: −0.0004/month, 95% CI: −0.0027 to 
0.0020) and a more modest decline in the PCV10 period 
(slope: −0.0014/month, 95% CI: −0.0193 to −0.0085; like-
lihood ratio test p<0.001).
The observed purchase RRs across the municipali-
ties with varying vaccination coverage are illustrated in 
figure 2. A sensitivity analysis showed no evidence that 
PCV vaccination coverage affected the association (all 
p values for interaction terms were larger than p=0.45).
DIsCussIOn
Our large population-based cohort study shows that 
replacement of PCV7 by PCV10 is associated with a 1.6% 
reduction in outpatient antibiotic use in Dutch infants. 
This is a far more modest decline than the 7% and 
17.5% decline observed in a Finnish cluster randomised 
controlled trial of PCV10 versus placebo and in a study 
using data from the Finnish social insurance institution.7 24 
Importantly, in addition to differences in study design, 
these Finnish studies assessed the impact of PCV10 in 
PCV naive children, whereas our study compared PCV10 
with PCV7.
So far, two observational studies have assessed the impact 
of introduction of PCV10 or PCV13 subsequent to PCV7 and 
focused on antibiotic prescribing for respiratory diseases 
including acute otitis media.25 26 Gefenaite et al25 found only 
a marginal percentage change in amoxicillin, azithromycin 
and sulfamethoxazole/trimethoprim prescriptions in 
Dutch infants aged 1 (−1.43%, 95% CI: −2.16% to −0.69%) 
and 2 years (−0.80%, 95% CI: −1.69% to 0.10%), respec-
tively.25 They, however, based their findings on information 
from 60 local pharmacies, and changes in population size 
over time were not taken into account.25While overcoming 
these methodological issues, our study results were more 
Table 1 Rate of observed antibiotic purchases,* Dutch infants aged under 2 years and changes in rates from PCV7 to PCV10
Number of
observed purchases Person-years
Rate per 1000
child-years 95% CI
Overall period† 275 337 461 352 597 595 to 599
PCV7 159 210 264 946 601 598 to 604
PCV10 116 127 196 406 591 588 to 595
Rate ratio 95% CI Change (%) 95% CI‡
PCV10 versus PCV7† 0.984 0.977 to 0.992 1.6 0.86 to 2.35
*Amoxicillin (J01CA04), amoxicillin/clavulanate (J01CR02), pheneticillin (J01CE05), phenoxymethylpenicillin (J01CE02) and trimethoprim/
sulfamethoxazole (J01EE01), azithromycin (J01FA10), clarithromycin (J01FA09).
†PCV7 period: January 2006 to February 2011; PCV10 period: March 2011 to December 2013.
‡Vaccine impact: percentage of change calculated using (1-rate ratio)×100.
PCV, pneumococcal conjugate vaccine. 
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or less similar, with a modest effect on antibiotic purchases. 
Lau et al26 studied UK children and found a 2.6% decline in 
antibiotic prescriptions specific to acute otitis media after 
switching from PCV7 to PCV13 in infants. PCV introduc-
tion in the Netherlands have led to a decline in pneumonia 
hospitalisations in children up to 2 years of age27 which is 
in line with the observed reductions in childhood invasive 
pneumococcal disease.28 Currently, data on the impact of 
PCVs on mild-to-moderate respiratory tract infections are, 
however, lacking. Moreover, any regional differences in the 
impact of PCV have not been studied, although regional 
clustering of unvaccinated children have led to outbreaks 
of, for example, vaccine-preventable measles disease in the 
Netherlands.29
Major strengths of our study are the large sample size, 
and the completeness and high validity of our dataset: 
we included infants registered with the health insurance 
company within the first 6 months of life and with all Dutch 
citizens having an obligatory basic healthcare insurance 
that covers costs of medication, our antibiotic data are 
Figure 1 Observed and estimated antibiotic purchase rates before and after pneumococcal conjugate vaccine 10 
implementation in Dutch infants aged under 2 years (rate per 1000 child-months). Observed monthly antibiotic purchase rates 
per 1000 child-months were calculated by dividing the number of antibiotic purchases by the total number of child-months. 
Estimated monthly antibiotic purchases were estimated using time-series analysis.
Figure 2 Observed rate ratios across municipalities with varying pneumococcal conjugate vaccine coverage. Vaccination 
coverage was categorised into seven groups (municipalities with a vaccination coverage <70%, between 70% and 75%, 75% 
and 80%, 80% and 85%, 85% and 90%, 90% and 95%, and >95%). Median purchase rate ratios (RRs) and IQRs for the seven 
groups are illustrated by box plots. Four outliers were excluded from the graph, but not from the analyses; these four observed 
RRs were between 3 and 4.
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reliable.14 Furthermore, neither new public health initia-
tives to reduce antibiotic prescribing that could have influ-
enced prescribing practices nor vaccination programmes 
other than PCV have been implemented during our study 
period. Finally, our quasi-experimental approach using 
interrupted time-series analysis makes full use of the longi-
tudinal nature of the data, accounts for preintervention 
trends and is therefore considered most optimal to study 
longitudinal effects of interventions using observational 
data.23 Our finding that PCV vaccination coverage did not 
modify the association between PCV10 introduction and 
antibiotic purchases might suggest that herd effects may be 
sufficiently strong to protect children in municipalities with 
a lower vaccine coverage against respiratory infections and 
associated antibiotic use or that the observed reduction is 
unrelated to PCV10 introduction. Nevertheless, the largest 
RRs (figure 2) were observed in municipalities with the 
lowest vaccine coverages and had very wide accompanying 
CIs. Our study might, therefore, have insufficient power to 
draw valid conclusions regarding the impact of vaccination 
coverage.
Limitations of our approach include confounding due 
to the observational nature of the study: temporal fluc-
tuations in risk factors for childhood respiratory tract 
infections and subsequent antibiotic prescribing such as 
breast feeding, household smoking, daycare attendance 
and differences in viral seasons may have impacted our 
findings.12 30–33 Furthermore, as influenza virus infec-
tions are linked to excess antibiotic prescribing in chil-
dren,34 the peak in antibiotic prescriptions in 2009 might 
be explained by the 2009 H1N1 pandemic. Second, the 
available follow-up time after PCV10 introduction (ie, 
2.5 years) is a limitation of our study and with the most 
prominent decline seen in 2013 (figure 1), future work 
should include longer follow-up data to fully quantify 
the impact of PCV10 on childhood antibiotic use. Third, 
antibiotic prescriptions issued between the date of birth 
and date of registration at the health insurance fund are 
missing from our dataset. With the majority of antibiotic 
prescriptions issued in children aged 3 months and above 
and with 95% of the children registered to the insurance 
fund in our dataset within the first month after birth, we 
consider the impact of these missing prescriptions on our 
results negligible. Fourth, misclassification in PCV vacci-
nation coverage might have occurred. However, vacci-
nation coverage was stable and very high (median 95%) 
over the entire study period (2006–2013). In 39 out of the 
46 municipalities (85%) with a vaccination coverage 
below 90% in 2012, the fluctuation in coverage over our 
study period was less than 5% point. The remaining seven 
municipalities had only a small number of children and 
were therefore more prone to larger fluctuations. By 
categorising vaccination coverage in 5% point groups, 
we deem misclassification negligible and to have no 
important influence on our results. Finally, the variation 
in PCV vaccination coverage in our study population may 
have been too small to detect potential effects on antibi-
otic use across groups.
COnClusIOns
Both crude and time-series analyses of nationwide empir-
ical data suggest that switching from PCV7 to PCV10 
resulted in a modest 1.6% reduction in outpatient anti-
biotic use in Dutch infants. There was no evidence that 
PCV vaccination coverage affected this association, but 
since the largest purchase RRs were observed in munic-
ipalities with the lowest vaccine coverage and had very 
wide accompanying CIs, our study might have insufficient 
power to detect such an association.
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